Loan Agreement and Note Payable dated October 11, 2022 - 2


LOAN AGREEMENT

October 11, 2022

 

THIS LOAN AGREEMENT (the “Agreement”) is entered into as of the 11th day of October, 2022 (the “Effective Date”) by and between CELL MEDX (CANADA) CORP., a corporation organized under the Business Corporations Act (British Columbia), and having an address at Suite 820 – 1130 West Pender Street, Vancouver, BC V6E 4A4 (the “Borrower”) and RICHARD NORMAN JEFFS, an individual with an address at 11750 Fairtide Road, Ladysmith, BC V9G 1K5 (the “Lender”).  

 

Whereas: 

 

A.The Lender advanced to the Borrower a total of USD$347,000 (the “Cash Advances”) during the period from June 22, 2021, up to and including October 3, 2022, for which advances the Borrower and the Lender had signed individual loan agreements and the Borrower issued separate notes payable accumulating 6% annual interest, compounded monthly (the “Accrued Interest”);  

 

B.The summary of the Cash Advances and the Accrued Interest is detailed in the Schedule “A” attached to this Agreement; and 

 

C.As at the date of this Agreement, the Lender wishes and the Borrower agrees to consolidate all Loan Agreements and associated with these Loan Agreements Notes Payable. 

 

It is agreed that: 

 

1.The Borrower and the Lender confirm the accuracy of the total amount due to the Lender as presented in the Schedule “A”, and agree that the total consolidated amount owed as at October 11, 2022, for Cash Advances and Accrued Interest accrued thereon is USD$353,511.56 (“Consolidated Principal”);  

 

2.This Agreement replaces all prior loan agreements between the Lender and the Borrower, as listed in the Schedule “A”, and as of October 11, 2022, these loan agreements are considered to be null and void;   

  

3.The Borrower agrees to repay the Consolidated Principal on demand, together with interest calculated and compounded monthly at the rate of 6% per year (the “Interest”) calculated from October 11, 2022 (the “Effective Date”);  

 

4.The Borrower understands that it is liable for repayment of the Consolidated Principal, accrued Interest, and any additional costs that the Lender incurs in trying to collect the amount owed to him under the terms of this Loan Agreement. 

 

5.The Borrower agrees that, upon a default of any payment of the amount owed under the Loan Agreement, the Lender will have full right and title of ownership to the Borrower’s intellectual property being eBalance (microcurrent) Technology, and any and all products developed by the Borrower that are based on the said eBalance (microcurrent) Technology, as well as all eBalance trademarks and certifications the Borrower has acquired.  

 

6.The Borrower will evidence the debt and its repayment of the Principal Sum and the Interest with a promissory note in the attached form. 

 

	LENDER

	BORROWER


	Richard N. Jeffs

	Cell MedX (Canada) Corp.


	 

	 


	Per:

	Per:


	 

	 


	 

	 


	/s/ Richard N. Jeffs

	/s/  Yanika Silina


	Richard N. Jeffs

	Yanika Silina, Director







PROMISSORY NOTE

 

	Consolidated Principal: USD$353,511.56

	October 11, 2022




 

 

FOR VALUE RECEIVED Cell MedX (Canada) Corp., (the “Borrower”) promises to pay on demand to the order of Richard N. Jeffs (the “Lender”) the sum of $353,511.56 lawful money of the United States of America (the “Consolidated Principal”) together with the Interest accrued on the Consolidated Principal calculated from October 11, 2022 (“Effective Date”) both before and after maturity, default and judgment at the Interest Rate as defined below.

 

For the purposes of this promissory note, Interest Rate means 6 per cent per year. Interest at the Interest Rate must be calculated and compounded monthly not in advance from and including the Effective Date (for an effective rate of 6.2% per annum calculated monthly), and is payable together with the Consolidated Principal when the Consolidated Principal is repaid.

 

As collateral for repayment of Consolidated Principal and the Interest, the Borrower agrees that, upon a default of any payment of the amount owed, the Lender will have full right and title of ownership to the Borrower’s intellectual property being eBalance (microcurrent) Technology, and any and all products developed by the Borrower that are based on the said eBalance (microcurrent) Technology, as well as all eBalance trademarks and certifications the Borrower has acquired. 

 

The Borrower may repay the Consolidated Principal and the Interest in whole or in part at any time.

 

The Borrower waives presentment, protest, notice of protest and notice of dishonor of this promissory note.

 

 

BORROWER

Cell MedX (Canada) Corp.

 

Per:

 

 

/s/ Yanika Silina

Yanika Silina, Director

 

 

 

 

 

 

 

 

 

 

 

 

 

  




SCHEDUEL “A”

TO THE LOAN AGREEMENT

Dated October 11, 2022

 

The following table presents the list of the cash advances that Lender had advanced to the Borrower during the period from June 22, 2021, up to and including October 3, 2022, which were borrowed pursuant to the individual loan agreements and for which the Borrower had issued notes payable. The total of these advances along with the interest accrued thereon are being consolidated into one Loan Agreement and consolidated Note Payable.  

 

	Loan Agreement Date

	Cash Advance

	Accrued Interest

	Total due

as at September 30, 2022


	June 22, 2021

	$    34,000.00

	$      793.11

	$   34,793.11


	October 7, 2021

	15,000.00

	343.81

	15,343.81


	October 26, 2021

	35,000.00

	799.74

	35,799.74


	November 24, 2021

	35,000.00

	795.94

	35,795.94


	December 30, 2021

	25,000.00

	565.18

	25,565.18


	January 27, 2022

	25,000.00

	562.60

	25,562.60


	February 24, 2022

	31,000.00

	694.42

	31,694.42


	April 28, 2022

	23,000.00

	509.92

	23,509.92


	May 31, 2022

	25,000.00

	551.27

	25,551.27


	June 27, 2022

	23,000.00

	403.35

	23,403.35


	July 28, 2022

	18,000.00

	222.80

	18,222.80


	August 31, 2022

	20,000.00

	134.97

	20,134.97


	September 6, 2022

	19,000.00

	109.45

	19,109.45


	October 3, 2022

	19,000.00

	24.99

	19,024.99


	Total

	$  347,000.00

	$  6,511.56

	$  353,511.56